Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

Roth MKM lowered the firm’s price target on Bio-Path (BPTH) to $9 from $12 and keeps a Buy rating on the shares. The company ended Q4 with $1.2M in cash, indicating Bio-Path requires near-term ...

MLB Opening Day 2025 is finally upon us and all eyes will be on the Los Angeles Dodgers after their World Series win in 2024. The Dodgers technically already opened their season with a sweep of ...

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical ...

Hillstar Bio is revolutionizing autoimmune disease treatment through a precision-driven approach that selectively depletes pathogenic cells while preserving healthy ones. This method holds the ...

Funding will support two Phase 2 clinical trials in alcohol and cocaine use disorders Company has initiated Phase 2 study in alcohol use disorder and plans to initiate cocaine studies over the ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...

March 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant.